Omega Fund Management, LLC reported 10 holdings worth US$125M as of Sep 30, 2026 (Form 13F)
As of Sep 30, 2026 · Filed Nov 16, 2026
Omega Fund Management, LLC reported 10 holdings worth US$125M as of Sep 30, 2026. Largest: Nuvation Bio Inc., Bicara Therapeutics Inc. and Beta Bionics, Inc. Filed Nov 16, 2026 (Form 13F).
- Holdings
- 10
- Value as reported
- US$125M
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|---|---|---|
| Nuvation Bio Inc. | 7.15M | US$40M | 32.0% |
| Bicara Therapeutics Inc. | 1.76M | US$32.8M | 26.2% |
| Beta Bionics, Inc. | 962K | US$18.3M | 14.6% |
| BridgeBio Oncology Therapeutics, Inc. | 3.29M | US$13.5M | 10.8% |
| Kestra Medical Technologies, Ltd. | 362K | US$10.3M | 8.2% |
| Immunic, Inc. | 430K | US$4M | 3.2% |
| Sana Biotechnology, Inc. | 844K | US$2.46M | 2.0% |
| ImageneBio, Inc. | 455K | US$2.09M | 1.7% |
| enGene Holdings Inc. | 876K | US$1.75M | 1.4% |
| Odyssey Therapeutics, Inc. | 2,893 | US$64,282 | 0.05% |
| Alumis Inc. | 0 | US$0 | 0.00% |
Source
Download original · View original at SEC